Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osiris Therapeutics, a stem cell therapeutic company, has completed enrollment in a human clinical trial designed to evaluate Prochymal, the company's proprietary formulation of adult mesenchymal stem cells, for the treatment of moderate to severe chronic obstructive pulmonary disease.
Subscribe to our email newsletter
A total of 62 patients were enrolled in the Phase II trial at six sites throughout the US. Osiris is investigating Prochymal in patients with chronic obstructive pulmonary disease (COPD), reported to be the fourth leading cause of death in the US.
Michelle Williams, vice president of development at Osiris, said: “We are excited to learn more about the therapeutic utility of these cells in the lungs, not only for the treatment of COPD, but for other pulmonary conditions as well. This study will provide for us the necessary base for further rapid development of this remarkable stem cell technology in what could ultimately prove to be a broad spectrum of lung diseases.”